Norvatis
-
Novartis acquires Excellergy for USD2B to develop next-generation allergy treatments
The acquisition signals Novartis’s confidence that Exl-111 can outperform this proven therapy by taking an entirely different approach.
-
Novartis commits USD480M to scale China operations amid multinational investment surge
Novartis will direct the funds toward upgrading its manufacturing plant in Beijing and expanding its R&D campus in Shanghai, where it also houses its Chinese headquarters.
-
Novartis acquires breakthrough breast cancer treatment in USD3B deal
The acquisition involves Novartis purchasing Pikavation Therapeutics, a wholly owned subsidiary of Synnovation Therapeutics that holds the rights to SNV4818 and related research programs.
-
Novartis receives FDA approval for Cosentyx to treat adolescents with Hidradenitis Suppurativa
The expansion of Cosentyx to this population addresses a critical gap in care and demonstrates Novartis’ focus on advancing solutions where the company can make the greatest impact on patient outcomes.
-
Novartis sells 71% stake in India unit to private equity consortium for USD159M
Novartis will continue operating its subsidiary Novartis Healthcare Private Limited, which serves as the commercial arm for the company’s operations in India.
-
Novartis breaks ground on USD23B US expansion with new San Diego research hub
The new San Diego facility will function as a critical node in Novartis’s integrated global research network, connecting seamlessly with existing research hubs in Basel, Switzerland, and Cambridge, Massachusetts.
-
Saudi Arabia advances chronic urticaria care through SSDDS-Novartis partnership
This partnership with Novartis creates a vital platform to increase awareness of chronic urticaria among dermatologists and other healthcare professionals.
-
Novartis to build new radioligand therapy manufacturing facility in Florida
This new 35,000 square foot, purpose-built site represents Novartis’s fourth dedicated RLT facility.